Serum M2BPGi as a predictor of hepatocellular carcinoma development in chronic hepatitis B and C: a systematic review and meta-analysis - Top-Institutions - MDSpire

Serum M2BPGi as a predictor of hepatocellular carcinoma development in chronic hepatitis B and C: a systematic review and meta-analysis

  • By

  • Yunchul Park

  • Younggoun Jo

  • Hyo-Sin Kim

  • Sola Lee

  • Hong-Sung Jung

  • Ho-Kyun Lee

  • Soo Jin Na Choi

  • July 15, 2026

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Tohoku University Hospital
    Tohoku University Hospital

    Sendai, Miyagi

    Key Differentiators

    • Hepatology

  • #2

    Asan Medical Center
    Asan Medical Center

    Seoul, South Korea

    Key Differentiators

    • Hepatology

  • #3

    First Affiliated Hospital of Chongqing Medical University
    First Affiliated Hospital of Chongqing Medical University

    Chongqing, China

    Key Differentiators

    • Hepatology

  • #4

    University of Texas Southwestern Medical Center
    University of Texas Southwestern Medical Center

    Dallas, Texas

    Key Differentiators

    • Hepatology

  • #5

    University of Ulsan College of Medicine
    University of Ulsan College of Medicine

    Seoul, South Korea

    Key Differentiators

    • Hepatology

Original Source(s)

Serum M2BPGi as a predictor of hepatocellular carcinoma development in chronic hepatitis B and C: a systematic review and meta-analysis

  • by Yunchul Park, Younggoun Jo, Hyo-Sin Kim, Sola Lee, Hong-Sung Jung, Ho-Kyun Lee, Soo Jin Na Choi

  • July 15, 2026

Related Content

Sequential tislelizumab plus bronchial arterial chemoembolization and systemic chemotherapy in advanced NSCLC with bulky tumors: efficacy and safety

Neoadjuvant chemotherapy with angiogenesis inhibitor in early-stage breast cancer: a systematic review and meta-analysis

Helicobacter pylori infection in gastric cancer patients in French Guiana: a hospital-based study (2018–2023)